Exciting news from Probe’s NanoDem project to develop a novel therapeutic drug monitoring point-of-care-testing device for the measurement of immunosuppressants in transplanted patients, based on the MicroEye®.
German partners at the Klinikum Rechts Der Isar Der Technischen University in Munich, have identified a new method to enhance the systems sensitivity as the focus is on measuring the important pharmacologically active fraction of the drugs administered rather than, as is current practice, determine total levels and then make assumptions on how well the drug is working.
The NanoDem project aims to set new standards in the care of transplant patients using Probe’s innovative MicroEye® device allied to analytical systems being developed by the other consortium patients; The Italian National Research Council, University of Tubingen, Datamed Srl, Universidad Complutense de Madrid, University of Stuttgart, INESC Microsistemas e Nanotecnologias, and Microfluidic ChipShop GmbH.
The project is an EU FP7 initiative with a budget of approximately €5 million. Clinical trials of the new TDM system should begin in 2014.
For more information see http://nanodem.ifac.cnr.it/